Healthcare

Bryan, Garnier & Co acts as Financial Advisor & Placement Agent on Abivax’s EUR 130 million Cross-over Financing

Abivax is a French listed, late-stage clinical biotech company mobilizing the body’s natural immune system machinery to treat patients with inflammatory diseases, viral infections and cancer

Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis (UC), Crohn’s disease (CD), rheumatoid arthritis (RA), and other inflammatory diseases, and liver cancer.

Capital raise proceeds will be mainly used for the continuation of the clinical programs of its lead product ABX 464 (obefazimod) and notably for further advancing the global phase 3 clinical study program in ulcerative colitis; financing of R&D, working capital and other general purposes of the Company; redemption of existing indebtedness.

Acting as Financial Advisor & Placement Agent, Bryan, Garnier & Co helped to deliver a EUR 130m cross-over financing for Abivax

The pricing was set at market price i.e. EUR 6.50.

Book was oversubscribed with high-quality US and European biotech specialist investors led by TCGX, with participation from existing investors Invus, Deep Track Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors, Great Point Partners, Commodore Capital, Samsara BioCapital, Boxer Capital and others.

This is Abivax’s fourth consecutive capital raise with Bryan, Garnier & Co and the 1st biotech capital raise on Euronext Paris 2023YTD, marking another landmark transaction for Bryan, Garnier & Co’s Healthcare and Equity Capital Markets franchises.

Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis.